CA Patent

CA3172166A1 — Formulation

Assigned to Union Therapeutics AS · Expires 2021-10-07 · 5y expired

What this patent protects

The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formulation, and provide high concentrations of s…

USPTO Abstract

The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formulation, and provide high concentrations of solubilised halogenated salicylanilide. Also disclosed a formulations in the form of powders and aerosols. Also disclosed are the formulations for use in the treatment of bacterial and viral infections, and the treatment of inflammatory diseases. The formulations are particularly suitable for administration by inhalation for the treatment of bacterial and viral pulmonary infections and the treatment of pulmonary inflammatory diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA3172166A1
Jurisdiction
CA
Classification
—
Expires
2021-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Union Therapeutics AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.